Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.61 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394432 | 0.86 | KEAP1 (0.53) | HIF1AHPGDMAPTMEN1CYP3A4 | |
| SCHEMBL16041940 | 0.83 | KEAP1 (0.54) | HIF1AHPGDMAPTMEN1CYP3A4 | |
| SCHEMBL10706602 | 0.83 | SRD5A2 (0.50) | HIF1AHPGDMAPTMEN1CYP3A4 | |
| SCHEMBL1418003 | 0.82 | HIF1A (0.59) | HIF1AHPGDMAPTMEN1CYP3A4 | |
| SCHEMBL3876954 | 0.82 | HIF1A (0.59) | HIF1AHPGDMAPTMEN1CYP3A4 | |
| SCHEMBL2578143 | 0.82 | CXCL8 (0.57) | MAPTMEN1KMT2ACASP1SMN1; SMN2 | |
| SCHEMBL29497752 | 0.82 | CXCL8 (0.57) | MAPTMEN1KMT2ACASP1SMN1; SMN2 | |
| SCHEMBL10834691 | 0.81 | EGFR (0.51) | HIF1AHPGDMAPTMEN1CYP3A4 | |
| SCHEMBL10834688 | 0.81 | EGFR (0.51) | HIF1AHPGDMAPTMEN1CYP3A4 | |
| SCHEMBL868684 | 0.80 | KEAP1 (0.51) | MAPTLMNASMN1; SMN2AKR1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
| EP-1945613-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007053082-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| US-7098212-B2 | Piperazine derivatives | BLUMBERG LAURA C | 2006-08-29 | — | — | US | disclosed |
| CN-1708304-A | Use of piperazine sulfonic acid derivatives as CCR1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders | PFIZER (US) | 2005-12-14 | — | — | CN | disclosed |
| US-6974817-B2 | CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP) | PFIZER INC. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1583533-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| CN-1668592-A | Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1 | PFIZER PROD INC (US) | 2005-09-14 | — | — | CN | disclosed |
| EP-1558258-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1534677-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | Pfizer Products Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040092529-A1 | Methods of using piperazine derivatives | PFIZER INC | 2004-05-13 | — | — | US | disclosed |
| US-20040063759-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2004009550-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | disclosed |
| WO-2003035627-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| EP-0609244-B1 | METHOD OF PREPARING HALOGENATED HYDROXYPHENYLACETIC ACIDS | BASF AG (DE) | 1998-12-23 | — | — | EP | disclosed |
| EP-0609244-A1 | METHOD OF PREPARING HALOGENATED HYDROXYPHENYLACETIC ACIDS | BASF Aktiengesellschaft (DE) | 1994-08-10 | — | — | EP | disclosed |
| WO-1993008294-A1 | METHOD OF PREPARING HALOGENATED HYDROXYPHENYLACETIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092529-A1 | Methods of using piperazine derivatives | CCR1, CCR3, CCR5 | HIF1A 1037/4885HPGD 1457/4885MAPT 4440/4885 |
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | HIF1A 1192/4885HPGD 2160/4885MAPT 4245/4885 |
| US-20030083335-A1 | Novel sulfonic acid derivatives | CCR1, MSR1, CXCR1 | HIF1A 1332/4885HPGD 3341/4885MAPT 4456/4885 |
| US-20040063759-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | HIF1A 2016/4885HPGD 3748/4885MAPT 4666/4885 |
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | HIF1A 129/4885HPGD 713/4885MAPT 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.